Showing results (11-20 of 119) with videos related to

Sort By:
Pageof 12
Urologic Oncology|August 7, 2025
Serum Markers as predictors for treatment benefit in castration-resistant prostate cancerTibor Szarvas, Gero Kramer, Kiran Jagarlamudi, et al.
World Journal of Urology|August 10, 2016
Cytoreductive radical prostatectomy in metastatic prostate cancer: Does it really make sense?Romain Mathieu, Stephan M Korn, Karim Bensalah, et al.
Current Opinion in Urology|May 27, 2020
The role of taxane-based chemotherapy in the treatment of prostate cancerNicolai A Huebner, Shahrokh F Shariat, Irene Resch, et al.
Acta Oncologica (Stockholm, Sweden)|July 9, 2011
Safety and efficacy of temsirolimus in heavily pretreated patients with metastatic renal cell carcinomaWolfgang Lamm, Ursula Maria Vogl, Marija Bojic, et al.
Reviews in Urology|September 21, 2006
The picture of the prostatic lymphokine network is becoming increasingly complexGeorg E Steiner, Bob Djavan, Gero Kramer, et al.
Medical Microbiology and Immunology|June 11, 2011
High detection rate of Trichomonas vaginalis in benign hyperplastic prostatic tissueDieter Mitteregger, Stephan W Aberle, Athanasios Makristathis, et al.
Clinical Nuclear Medicine|July 1, 2020
Dose Calculations and Dose-Effect Relationships in 177Lu-PSMA I&T Radionuclide Therapy for Metastatic Castration-Resistant Prostate CancerSandra Barna, Alexander R Haug, Markus Hartenbach, et al.
European Journal of Nuclear Medicine and Molecular Imaging|April 22, 2025
Genomic instability is associated with response to [¹⁷⁷Lu]Lu-PSMA-I&T radioligand therapy: an exploratory, preliminary liquid biopsy analysisKilian Kluge, David Haberl, Alexander Haug, et al.
Pageof 12